Journal article

B-type natriuretic peptide concentrations and myocardial dysfunction in critical illness

DJ Sturgess, TH Marwick, CJ Joyce, B Venkatesh

ANAESTHESIA AND INTENSIVE CARE | AUSTRALIAN SOC ANAESTHETISTS | Published : 2006

Abstract

B-type natriuretic peptide (BNP) is the first biomarker of proven value in screening for left ventricular dysfunction. The availability of point-of-care testing has escalated clinical interest and the resultant research is defining a role for BNP in the investigation and treatment of critically ill patients. This review was undertaken with the aim of collecting and assimilating current evidence regarding the use of BNP assay in the evaluation of myocardial dysfunction in critically ill humans. The information is presented in a format based upon organ system and disease category. BNP assay has been studied in a spectrum of clinical conditions ranging from acute dyspnoea to subarachnoid haemor..

View full abstract